Live Breaking News & Updates on Adverum Biotechnologies Company Profile

Stay updated with breaking news from Adverum biotechnologies company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Buy" from Analysts

Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) has received an average rating of “Buy” from the four brokerages that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the […] ....

Newtyn Management , Adverum Biotechnologies Inc , Citigroup Inc , Adverum Biotechnologies Company Profile , Capital Partners , Avoro Capital Advisors , Adverum Biotechnologies , Get Free Report , Marketbeat Ratings , Capital Advisors , Mahoney Asset Management , Twin Focus Capital Partners , Get Free , Adverum Biotechnologies Daily ,

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Buy" from Brokerages

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Buy" from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

James Paul Scopa , Citigroup Inc , Worth Venture Partners , Capital Management , Vivo Capital , Securities Exchange Commission , Adverum Biotechnologies Company Profile , Adverum Biotechnologies Inc , Adverum Biotechnologies , Get Free Report , Chardan Capital , Director James Paul Scopa , Exchange Commission , Venture Partners , Get Free , Adverum Biotechnologies Daily ,

Adverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […] ....

James Paul Scopa , Adverum Biotechnologie , Newtyn Management , Citigroup Inc , Capital Management , Adverum Biotechnologies Inc , Adverum Biotechnologies Company Profile , Adverum Biotechnologies , Free Report , Moderate Buy , Get Free Report , Director James Paul Scopa , Asset Management , Apexium Financial , Adverum Biotechnologies Daily , Nasdaq Advm , Initiated Coverage , Hc Wainwright ,

Adverum Biotechnologies (NASDAQ:ADVM) Price Target Lowered to $22.00 at Mizuho

Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […] ....

James Paul Scopa , Adverum Biotechnologies Company Profile , Capital Management , Adverum Biotechnologies Inc , Newtyn Management , Securities Exchange Commission , Citigroup Inc , Adverum Biotechnologies , Free Report , Moderate Buy , Get Free Report , Director James Paul Scopa , Exchange Commission , Asset Management , Apexium Financial , Adverum Biotechnologies Daily , Nasdaq Advm , Lower Price Target ,

Adverum Biotechnologies (NASDAQ:ADVM) Upgraded at StockNews.com

StockNews.com upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday. A number of other equities analysts have also recently commented on ADVM. Mizuho lifted their price target on Adverum Biotechnologies from $20.00 to $40.00 and gave the stock […] ....

James Paul Scopa , Cantor Fitzgerald , Adverum Biotechnologies Company Profile , Adverum Biotechnologies Inc , Geode Capital Management , Topco Ltd , York Mellon Corp , Adverum Biotechnologies , Free Report , Get Free Report , Director James Paul Scopa , New York Mellon Corp , Capital Management , Monaco Asset Management , Asset Management , Adverum Biotechnologies Daily , Nasdaq Advm , Stocknews Com ,